Answers are grounded in this paper and cite their sources.
Proof-of-concept study demonstrates temtokibart's clinical effectiveness and safety in atopic dermatitis, implying potential for new treatments.
This proof-of-concept study demonstrates that targeting the IL-22 pathway with temtokibart is clinically effective with a favorable safety profile.
No takes yet. Share an insight, caveat, or question.
Thaçi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: